DPP IV INHIBITORS AS ANTIDIABETICS

Author(s): Chavan Prerana A.* and Jadhav Shailaja B

Abstract: A new therapy used for treating type 2 diabetes which reduces glucagon and postprandial glucose levels is Incretin based therapy. This therapy provides long term therapeutic benefits by restoring beta cells. The most important incretin hormones called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which stimulates insulin secretion in response to meals gets inactivated by proteolytic enzyme dipeptidyl peptidase – IV. This leads to the development of DPP – IV inhibitors for the treatment of type 2 diabetes. The present review focuses on the various reported DPP IV inhibitor derivatives as well as DPP-IV-resistant GLP-1 or GIP analogs.

PAGES: 322-328  |  89 VIEWS  199 DOWNLOADS